Review FASEB journal · 2026 The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease: From Mechanistic Insights to Precision Therapeutics. Zhu S, Zou M, Wu Q, et al. Akkermansia muciniphila PubMed ↗
Systematic review Current obesity reports · 2026 The Role of Butyrate in People with Metabolic Dysfunction-Associated Steatotic Liver Disease and Related Metabolic Comorbidities: A Systematic Review. González-González A, Soria-Utrilla V, Fontalba-Romero MI, et al. Faecalibacterium prausnitzii PubMed ↗
Observational BMC microbiology · 2025 High alcohol-producing Escherichia coli causes obesity and steatotic liver disease in a non-alcoholic cohort -a preclinical study. Singh A, Singh DN, Singh AN, et al. Escherichia coli PubMed ↗
Systematic review BMC gastroenterology · 2025 Therapeutic potential of Akkermansia muciniphila in non-alcoholic fatty liver disease: a systematic review. Asghari P, Ahmadi-Khorram M, Hatami A, et al. Akkermansia muciniphila PubMed ↗
Randomized trial Journal of agricultural and food chemistry · 2025 Hydroxytyrosol Improves Metabolic Dysfunction-Associated Fatty Liver Disease Dependent on the Modulation of Gut Microbiota. Xiao Y, Zhang X, Shao B, et al. Fusicatenibacter saccharivorans PubMed ↗
Observational mSystems · 2025 Multi-omics analyses of the gut microbiota and metabolites in children with metabolic dysfunction-associated steatotic liver disease. Du L, Zhang K, Liang L, et al. [Ruminococcus] torques PubMed ↗
Review Current nutrition reports · 2024 The Interplay Between Dietary Choline and Cardiometabolic Disorders: A Review of Current Evidence. Vallianou NG, Kounatidis D, Psallida S, et al. Akkermansia muciniphilaFaecalibacterium prausnitzii PubMed ↗
Review Hepatology communications · 2024 Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease. Long Q, Luo F, Li B, et al. Akkermansia muciniphila PubMed ↗
Review Archives of microbiology · 2024 Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets. Gruzdev SK, Podoprigora IV, Gizinger OA Escherichia coliKlebsiella pneumoniae PubMed ↗
Observational Wiadomosci lekarskie · 2024 Differentiated approach to management of patients with irritable bowel syndrome and ulcerative colitis in non-alcoholic fatty liver disease. Sirchak YS, Kornash VV, Dutko OO, et al. Escherichia coli PubMed ↗
Randomized trial The American journal of clinical nutrition · 2023 Effect of an Asian-adapted Mediterranean diet and pentadecanoic acid on fatty liver disease: the TANGO randomized controlled trial. Chooi YC, Zhang QA, Magkos F, et al. Bifidobacterium adolescentis PubMed ↗
Randomized trial Cell metabolism · 2023 Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations. Ni Y, Qian L, Siliceo SL, et al. Bacteroides stercoris PubMed ↗
Randomized trial The Journal of nutrition · 2023 Probiotic Supplementation, Hepatic Fibrosis, and the Microbiota Profile in Patients with Nonalcoholic Steatohepatitis: A Randomized Controlled Trial. Escouto GS, Port GZ, Tovo CV, et al. Bifidobacterium animalis PubMed ↗
Review Frontiers of medicine · 2022 Role of Akkermansia muciniphila in the development of nonalcoholic fatty liver disease: current knowledge and perspectives. Han Y, Li L, Wang B Akkermansia muciniphila PubMed ↗
Randomized trial Annals of hepatology · 2022 Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: A double-blind placebo-controlled randomized study. Barcelos STA, Silva-Sperb AS, Moraes HA, et al. Bifidobacterium animalis PubMed ↗
Randomized trial Cellular and molecular biology · 2022 Effects of Clostridium butyricum Capsules Combined with Rosuvastatin on Intestinal Flora, Lipid Metabolism, Liver Function and Inflammation in NAFLD Patients. Zhu W, Yan M, Cao H, et al. Agathobacter rectalisBacteroides thetaiotaomicron PubMed ↗
Review Obesity reviews · 2022 Human microbiome and metabolic health: An overview of systematic reviews. Michels N, Zouiouich S, Vanderbauwhede B, et al. Akkermansia muciniphilaBacteroides fragilisBifidobacterium animalisPhocaeicola vulgatus PubMed ↗
Observational AIDS · 2022 A pilot study of microbial signatures of liver disease in those with HIV mono-infection in Rio de Janeiro, Brazil. Yanavich C, Perazzo H, Li F, et al. Agathobacter rectalisAkkermansia muciniphilaBacteroides fragilisBacteroides stercoris +5 more PubMed ↗
Review Biomolecules · 2021 Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. Vallianou N, Christodoulatos GS, Karampela I, et al. Akkermansia muciniphilaFaecalibacterium prausnitziiSegatella copri PubMed ↗
Observational Physiological genomics · 2021 Alterations in bile acid metabolizing gut microbiota and specific bile acid genes as a precision medicine to subclassify NAFLD. Jiao N, Loomba R, Yang ZH, et al. Bacteroides ovatus PubMed ↗